Stay updated on RX-5902 in Triple Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the RX-5902 in Triple Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the RX-5902 in Triple Negative Breast Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the treatment of subjects with triple negative breast cancer using the drug RX-5902 in a Phase 2 study.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:22.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals with histologically confirmed triple negative breast cancer who meet certain health conditions and treatment histories. Previously, this section had no information provided.
    Difference
    27%
    Check dated 2024-05-22T21:16:05.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:29:22.000Z thumbnail image

Stay in the know with updates to RX-5902 in Triple Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the RX-5902 in Triple Negative Breast Cancer Clinical Trial page.